The Committee for Medicinal Products for Human Use (CHMP) is the European Medicines Agency's (EMA) committee responsible for human medicines. It plays a vital role in the authorisation of medicines in the European Union. The committee meets once a month. EMA publishes agendas, minutes and highlights of its plenary meetings.

Dec 12, 2024 · EMA’s human medicines committee (CHMP) recommended seventeen medicines for approval at its December 2024 meeting. This brings the total number of medicines recommended for approval in 2024 to 114.

The European Medicines Agency (EMA) publishes details of the members and alternates of its Committee for Medicinal Products for Human Use (CHMP).

The committee that is responsible for preparing the Agency's opinions on questions concerning human medicines. Abbreviated as CHMP. More information can be found under 'Committee for Medicinal Products for Human Use (CHMP)'.

Nov 14, 2024 · EMA’s human medicines committee (CHMP) recommended eight medicines for approval at its November 2024 meeting. The committee recommended granting a conditional marketing authorisation for Augtyro (repotrectinib), a medicine intended for the treatment of adults and adolescents with advanced solid tumours, and adults with locally advanced or ...

developed a multi-annual workplan on AI to enable the safe and responsible use of AI in the medicine lifecycle and extract value for public and animal health. In addition, the EMRN strategy to 2028 reflects

Apr 25, 2024 · EMA’s human medicines committee (CHMP) recommended eight medicines for approval at its April 2024 meeting. The CHMP recommended granting a marketing authorisation for Altuvoct* (efanesoctocog alfa), for the treatment and prophylaxis of bleeding in patients with haemophilia A, a rare inherited bleeding disorder caused by lack of factor VIII.

The Committee for Medicinal Products for Human Use (Committee), being part of the Agency, is responsible for preparing the opinion of the Agency on any question relating to the evaluation of medicinal products for human use, relying on the scientific evaluation and resources available to

Jul 15, 2024 · EMA guidance documents on the use of medicinal products for treatment in case of exposure to Biological or Chemical agents used as weapons of terrorism, crime, or warfare.................................................................................................................21

Committee for medicinal products for human use (CHMP) Draft agenda for the meeting on 11-14 November 2024 Chair: Bruno Sepodes – Vice-Chair: Outi Mäki-Ikola